目的：比较二甲双胍联合瑞格列奈或阿卡波糖对2型糖尿病心血管病变危险因素的影响。方法选择2014年1~12月我院收入治疗的初诊2型糖尿病患者60例,随机为对照组和观察组,每组30例,对照组患者采用二甲双胍联合阿卡波糖治疗,观察组患者采用二甲双胍联合瑞格列奈治疗,均治疗12周,比较两组患者治疗前后的血糖(FBG 和2hBG)、血脂(HDL、LDL)、全血黏度、人体质量指数(BMI)、超敏 C 反应蛋白(hs-CRP)等心血管病变危险因素相关指标的数据差异。结果两组患者治疗后的血糖、LDL、hs-CRP 及血浆黏度均较治疗前改善,P <0.05；同时观察组患者治疗后的 FBG、2hBG、hs-CRP 及血浆黏度与对照组比较,差异具有统计学意义(P <0.05)。结论二甲双胍联合瑞格列奈治疗2型糖尿病患者不仅可以有效降低患者的血糖,同时可以调节患者血脂,改善患者的血管内皮功能及血浆黏度,较好地控制了心血管病变的危险因素。%Objective To compare the influence of Metformin combined Repaglinide and Metformin com-bined Acarbose on the cardiovascular disease risk factors for type 2 diabetic patients. Methods Sixty type 2 diabetic patients cared at our hospital between January and December 2014 were randomly divided into a control group and an observation group,each had 30 cases.Patients of the control group treated with Metformin and Repaglinide,patients of observation group treated with Metformin and Acarbose,all patients received 12 -week treatment.Compared the blood glucose (FBG and 2hBG),blood lipids (HDL and LDL),whole blood viscosity,body mass index (BMI),high-sensitivity C-reactive protein data (hs-CRP)and other cardiovas-cular disease risk factors related indicators of two groups patients before and after treatment. Results Post-treatment blood glucose,LDL,hs-CRP and plasma viscosity were greatly improved and better than those of pre-treatment,compared post - treatment with pre - treatment within the two groups showed statistically differences,P < 0.05.While post - treatment FBG,2hBG,hs - CRP,and plasma viscosity in observation group patients were significantly different with those of control group patients (P < 0.05 ). Conclusion Metformin plus Repaglinide in type 2 diabetic patients not only can effectively lower blood sugar,and can regu-late blood lipids,improve endothelial function and plasma viscosity of patients,better control the risk factors for cardiovascular disease.
展开▼
